Preferred Label : Remestemcel-L;
NCIt synonyms : Allogeneic Adult Mesenchymal Stem Cells; Allogeneic Adults MSCs; Allogeneic Expanded Mesenchymal Stem Cells;
NCIt definition : Human mesenchymal stem cells (MSCs) harvested from bone marrow of healthy adult donors
and expanded ex vivo, with potential immunosuppressive application. Allogeneic adult
MSCs are hypo-immunogenic due to lack of major histocompatibility II (MHC II) molecule
expression, and thereby elicit none or minimal immune response upon intravenous infusion.
MSCs are pluripotent, and are capable of being recruited to damaged tissue sites and
differentiating along specific lineages when stimulated. Infusion of MSCs results
in: a) increased production of anti-inflammatory cytokines, such as interleukin-10,
prostaglandin E, and hepatocyte growth factor; b) decreased mononuclear phagocyte
expression of indoleamine 2,3,-dioxygenase, which catabolizes L-tryptophan into its
metabolites, which in turn contribute to inflammation; and c) modulated dendritic
cell maturation and disrupted activities of natural killer cells, CD8 and CD4 T
cells.;
UNII : H57D26Z9YK;
Drug name : Prochymal;
Molecule name : JR-0301;
Origin ID : C67082;
UMLS CUI : C1879680;
Currated CISMeF NLP mapping
Semantic type(s)
- Cell [UMLS semantic type]
UMLS correspondences (same concept)
concept_is_in_subset
Summary Basis of Decision (SBD) for Prochymal
Remestemcel-L, Adult Human Mesenchymal Stem Cells (hMSCs) 100 106 hMSCs per 15 mL,
cell suspension
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00118
2012
false
Canada
French
English
Remestemcel-L
drug information
Product containing human mesenchymal stem cell (medicinal product)
Human mesenchymal stem cell (substance)
Mesenchymal Stem Cells
drug approval
canada
graft vs host disease
acute disease
child
treatment outcome
drug compounding
infusions, intravenous
drug evaluation
risk assessment
---